315 related articles for article (PubMed ID: 24656971)
1. Illicit dopamine transients: reconciling actions of abused drugs.
Covey DP; Roitman MF; Garris PA
Trends Neurosci; 2014 Apr; 37(4):200-10. PubMed ID: 24656971
[TBL] [Abstract][Full Text] [Related]
2. Amphetamine paradoxically augments exocytotic dopamine release and phasic dopamine signals.
Daberkow DP; Brown HD; Bunner KD; Kraniotis SA; Doellman MA; Ragozzino ME; Garris PA; Roitman MF
J Neurosci; 2013 Jan; 33(2):452-63. PubMed ID: 23303926
[TBL] [Abstract][Full Text] [Related]
3. Electrophysiological correlates of abused drugs: relation to natural rewards.
Deadwyler SA
Ann N Y Acad Sci; 2010 Feb; 1187():140-7. PubMed ID: 20201851
[TBL] [Abstract][Full Text] [Related]
4. VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse.
Eiden LE; Weihe E
Ann N Y Acad Sci; 2011 Jan; 1216():86-98. PubMed ID: 21272013
[TBL] [Abstract][Full Text] [Related]
5. Differential influence of dopamine transport rate on the potencies of cocaine, amphetamine, and methylphenidate.
Calipari ES; Ferris MJ; Siciliano CA; Jones SR
ACS Chem Neurosci; 2015 Jan; 6(1):155-62. PubMed ID: 25474655
[TBL] [Abstract][Full Text] [Related]
6. Good riddance to dopamine: roles for the dopamine transporter in synaptic function and dopamine-associated brain disorders.
Gowrishankar R; Hahn MK; Blakely RD
Neurochem Int; 2014 Jul; 73():42-8. PubMed ID: 24231471
[TBL] [Abstract][Full Text] [Related]
7. Amphetamine activates Rho GTPase signaling to mediate dopamine transporter internalization and acute behavioral effects of amphetamine.
Wheeler DS; Underhill SM; Stolz DB; Murdoch GH; Thiels E; Romero G; Amara SG
Proc Natl Acad Sci U S A; 2015 Dec; 112(51):E7138-47. PubMed ID: 26553986
[TBL] [Abstract][Full Text] [Related]
8. Nonclassical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators, and partial substrates.
Schmitt KC; Rothman RB; Reith ME
J Pharmacol Exp Ther; 2013 Jul; 346(1):2-10. PubMed ID: 23568856
[TBL] [Abstract][Full Text] [Related]
9. Fluctuation of the dopamine uptake inhibition potency of cocaine, but not amphetamine, at mammalian cells expressing the dopamine transporter.
Ukairo OT; Ramanujapuram S; Surratt CK
Brain Res; 2007 Feb; 1131(1):68-76. PubMed ID: 17169338
[TBL] [Abstract][Full Text] [Related]
10. Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse.
Schmitt KC; Reith ME
Ann N Y Acad Sci; 2010 Feb; 1187():316-40. PubMed ID: 20201860
[TBL] [Abstract][Full Text] [Related]
11. Differential targeting of the dopamine transporter to recycling or degradative pathways during amphetamine- or PKC-regulated endocytosis in dopamine neurons.
Hong WC; Amara SG
FASEB J; 2013 Aug; 27(8):2995-3007. PubMed ID: 23612789
[TBL] [Abstract][Full Text] [Related]
12. The dopamine transporter: a vigilant border control for psychostimulant action.
Williams JM; Galli A
Handb Exp Pharmacol; 2006; (175):215-32. PubMed ID: 16722238
[TBL] [Abstract][Full Text] [Related]
13. Dopamine and Addiction.
Wise RA; Robble MA
Annu Rev Psychol; 2020 Jan; 71():79-106. PubMed ID: 31905114
[TBL] [Abstract][Full Text] [Related]
14. Context-Dependent Multiplexing by Individual VTA Dopamine Neurons.
Kremer Y; Flakowski J; Rohner C; Lüscher C
J Neurosci; 2020 Sep; 40(39):7489-7509. PubMed ID: 32859713
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain.
Freyberg Z; Sonders MS; Aguilar JI; Hiranita T; Karam CS; Flores J; Pizzo AB; Zhang Y; Farino ZJ; Chen A; Martin CA; Kopajtic TA; Fei H; Hu G; Lin YY; Mosharov EV; McCabe BD; Freyberg R; Wimalasena K; Hsin LW; Sames D; Krantz DE; Katz JL; Sulzer D; Javitch JA
Nat Commun; 2016 Feb; 7():10652. PubMed ID: 26879809
[TBL] [Abstract][Full Text] [Related]
16. G protein-coupled receptor signaling in VTA dopaminergic neurons bidirectionally regulates the acute locomotor response to amphetamine but does not affect behavioral sensitization.
Runegaard AH; Dencker D; Wörtwein G; Gether U
Neuropharmacology; 2019 Dec; 161():107663. PubMed ID: 31173760
[TBL] [Abstract][Full Text] [Related]
17. Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems.
Hall FS; Itokawa K; Schmitt A; Moessner R; Sora I; Lesch KP; Uhl GR
Neuropharmacology; 2014 Jan; 76 Pt A(0 0):146-55. PubMed ID: 23978383
[TBL] [Abstract][Full Text] [Related]
18. The neuroscience of natural rewards: relevance to addictive drugs.
Kelley AE; Berridge KC
J Neurosci; 2002 May; 22(9):3306-11. PubMed ID: 11978804
[No Abstract] [Full Text] [Related]
19. Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine.
Kahlig KM; Galli A
Eur J Pharmacol; 2003 Oct; 479(1-3):153-8. PubMed ID: 14612146
[TBL] [Abstract][Full Text] [Related]
20. Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse.
Zhu J; Reith ME
CNS Neurol Disord Drug Targets; 2008 Nov; 7(5):393-409. PubMed ID: 19128199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
